Download PDF
Semin Respir Crit Care Med 2007; 28(3): 312-321
DOI: 10.1055/s-2007-981652
Copyright © 2007 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Emerging and Unusual Gram-Negative Infections in Cystic Fibrosis

Jane C. Davies1 , 2 , Bruce K. Rubin3 , 4
  • 1Department of Pediatric Respiratory Medicine, Royal Brompton Hospital, London, United Kingdom
  • 2Department of Gene Therapy, Imperial College, London, United Kingdom
  • 3Department of Pediatrics, Physiology, and Pharmacology, Wake Forest University School of Medicine, Winston-Salem, North Carolina
  • 4Department of Biomedical Engineering, Virginia Polytechnic Institute/Wake Forest University, North Carolina
Further Information

Publication History

Publication Date:
22 August 2007 (online)

    Permissions and Reprints

ABSTRACT

People with cystic fibrosis (CF) have chronic airway infection and frequent exposure to antibiotics, which often leads to the emergence of resistant organisms. In addition to the development of multiresistance in common CF pathogens such as Pseudomonas aeruginosa, several newer, inherently resistant gram-negative species are becoming more common, including Burkholderia cepacia complex, Stenotrophomonas maltophilia, Achromobacter (Alcaligenes) xylosoxidans, certain Ralstonia species, and those within the new genus Pandoraea. Many of these are closely related and have similar phenotypes, making accurate laboratory identification challenging. Although their role in contributing to pulmonary disease in CF is not clear, some, such as those of the B. cepacia complex, are clearly linked to an adverse prognosis, and both treatment and infection control issues can pose a real challenge.

KEYWORDS

Burkholderia cepacia - Stenotrophomonas maltophilia - Achromobacter (Alcaligenes) xylosoxidans - Ralstonia spp. - Pandoraea spp

REFERENCES

  • 1 Davies J C. Pseudomonas aeruginosa in cystic fibrosis: pathogenesis and persistence.  Paediatr Respir Rev. 2002;  3 128-134
    CrossrefPubMedGoogle Scholar
  • 2 Matsui H, Grubb B R, Tarran R et al.. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease.  Cell. 1998;  95 1005-1015
    CrossrefPubMedGoogle Scholar
  • 3 Saiman L, Prince A. Pseudomonas aeruginosa pili bind to asialo GM1 which is increased on the surface of cystic fibrosis epithelial cells.  J Clin Invest. 1993;  92 1875-1880
    PubMedGoogle Scholar
  • 4 Pier G B, Grout M, Zaidi T S et al.. Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections.  Science. 1996;  271 64-67
    CrossrefPubMedGoogle Scholar
  • 5 Worlitzsch D, Tarran R, Ulrich M et al.. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients.  J Clin Invest. 2002;  109 317-325
    CrossrefPubMedGoogle Scholar
  • 6 Henke M O, Renner A, Huber R M, Seeds M C, Rubin B K. MUC5AC and MUC5B mucins are decreased in cystic fibrosis airway secretions.  Am J Respir Cell Mol Biol. 2004;  31 86-91
    CrossrefPubMedGoogle Scholar
  • 7 Ratjen F. Diagnosing and managing infection in CF.  Paediatr Respir Rev. 2006;  7 S151-S153
    CrossrefPubMedGoogle Scholar
  • 8 Corey M, Farewell V. Determinants of mortality from cystic fibrosis in Canada, 1970-1989.  Am J Epidemiol. 1996;  143 1007-1017
    PubMedGoogle Scholar
  • 9 Coenye T, LiPuma J J. Molecular epidemiology of Burkholderia species.  Front Biosci. 2003;  8 E55-E67
    PubMedGoogle Scholar
  • 10 LiPuma J J, Spilker T, Gill L H, Campbell III P W, Liu L, Mahenthiralingam E. Disproportionate distribution of Burkholderia cepacia complex species and transmissibility markers in cystic fibrosis.  Am J Respir Crit Care Med. 2001;  164 92-96
    CrossrefPubMedGoogle Scholar
  • 11 McMenamin J D, Zaccone T M, Coenye T, Vandamme P, LiPuma J J. Misidentification of Burkholderia cepacia in US cystic fibrosis treatment centers: an analysis of 1,051 recent sputum isolates.  Chest. 2000;  117 1661-1665
    CrossrefPubMedGoogle Scholar
  • 12 http://go.to/cepacia
  • 13 Pegues D A, Carson L A, Tablan O C et al.. Acquisition of Pseudomonas cepacia at summer camps for patients with cystic fibrosis. Summer Camp Study Group.  J Pediatr. 1994;  124 694-702
    PubMedGoogle Scholar
  • 14 Sun L, Jiang R Z, Steinbach S et al.. The emergence of a highly transmissible lineage of cbl + Pseudomonas (Burkholderia) cepacia causing CF centre epidemics in North America and Britain.  Nat Med. 1995;  1 661-666
    CrossrefPubMedGoogle Scholar
  • 15 Mahenthiralingam E, Simpson D A, Speert D P. Identification and characterization of a novel DNA marker associated with epidemic Burkholderia cepacia strains recovered from patients with cystic fibrosis.  J Clin Microbiol. 1997;  35 808-816
    PubMedGoogle Scholar
  • 16 Chen J S, Witzmann K A, Spilker T, Fink R J, LiPuma J J. Endemicity and inter-city spread of Burkholderia cepacia genomovar III in cystic fibrosis.  J Pediatr. 2001;  139 643-649
    CrossrefPubMedGoogle Scholar
  • 17 Holmes A, Nolan R, Taylor R et al.. An epidemic of Burkholderia cepacia transmitted between patients with and without cystic fibrosis.  J Infect Dis. 1999;  179 1197-1205
    CrossrefPubMedGoogle Scholar
  • 18 Sajjan U S, Yang J H, Hershenson M B, LiPuma J J. Intracellular trafficking and replication of Burkholderia cenocepacia in human cystic fibrosis airway epithelial cells.  Cell Microbiol. 2006;  8 1456-1466
    CrossrefPubMedGoogle Scholar
  • 19 Saini L S, Galsworthy S B, John M A, Valvano M A. Intracellular survival of Burkholderia cepacia complex isolates in the presence of macrophage cell activation.  Microbiology. 1999;  145 3465-3475
    PubMedGoogle Scholar
  • 20 Lamothe J, Huynh K K, Grinstein S, Valvano M A. Intracellular survival of Burkholderia cenocepacia in macrophages is associated with a delay in the maturation of bacteria-containing vacuoles.  Cell Microbiol. 2007;  9 40-53
    CrossrefPubMedGoogle Scholar
  • 21 Shaw D, Poxton I R, Govan J R. Biological activity of Burkholderia (Pseudomonas) cepacia lipopolysaccharide.  FEMS Immunol Med Microbiol. 1995;  11 99-106
    PubMedGoogle Scholar
  • 22 Conway B A, Venu V, Speert D P. Biofilm formation and acyl homoserine lactone production in the Burkholderia cepacia complex.  J Bacteriol. 2002;  184 5678-5685
    CrossrefPubMedGoogle Scholar
  • 23 Lessie T G, Hendrickson W, Manning B D, Devereux R. Genomic complexity and plasticity of Burkholderia cepacia .  FEMS Microbiol Lett. 1996;  144 117-128
    CrossrefPubMedGoogle Scholar
  • 24 Moore R A, Hancock R E. Involvement of outer membrane of Pseudomonas cepacia in aminoglycoside and polymyxin resistance.  Antimicrob Agents Chemother. 1986;  30 923-926
    PubMedGoogle Scholar
  • 25 Aronoff S C. Derepressed beta-lactamase production as a mediator of high-level beta-lactam resistance in Pseudomonas cepacia .  Pediatr Pulmonol. 1988;  4 72-77
    CrossrefPubMedGoogle Scholar
  • 26 Wigfield S M, Rigg G P, Kavari M, Webb A K, Matthews R C, Burnie J P. Identification of an immunodominant drug efflux pump in Burkholderia cepacia .  J Antimicrob Chemother. 2002;  49 619-624
    CrossrefPubMedGoogle Scholar
  • 27 Tablan O C, Martone W J, Doershuk C F et al.. Colonization of the respiratory tract with Pseudomonas cepacia in cystic fibrosis: risk factors and outcomes.  Chest. 1987;  91 527-532
    CrossrefPubMedGoogle Scholar
  • 28 Aris R M, Routh J C, LiPuma J J, Heath D G, Gilligan P H. Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex: survival linked to genomovar type.  Am J Respir Crit Care Med. 2001;  164 2102-2106
    CrossrefPubMedGoogle Scholar
  • 29 Soni R, Marks G, Henry D A et al.. Effect of Burkholderia cepacia infection in the clinical course of patients with cystic fibrosis: a pilot study in a Sydney clinic.  Respirology. 2002;  7 241-245
    CrossrefPubMedGoogle Scholar
  • 30 Kalish L A, Waltz D A, Dovey M et al.. Impact of Burkholderia dolosa on lung function and survival in cystic fibrosis.  Am J Respir Crit Care Med. 2006;  173 421-425
    CrossrefPubMedGoogle Scholar
  • 31 Ledson M J, Gallagher M J, Corkill J E, Hart C A, Walshaw M J. Cross infection between cystic fibrosis patients colonised with Burkholderia cepacia .  Thorax. 1998;  53 432-436
    CrossrefPubMedGoogle Scholar
  • 32 Golini G, Cazzola G, Fontana R. Molecular epidemiology and antibiotic susceptibility of Burkholderia cepacia-complex isolates from an Italian cystic fibrosis centre.  Eur J Clin Microbiol Infect Dis. 2006;  25 175-180
    CrossrefPubMedGoogle Scholar
  • 33 Fass R J, Barnishan J, Solomon M C, Ayers L W. In vitro activities of quinolones, beta-lactams, tobramycin, and trimethoprim-sulfamethoxazole against nonfermentative gram-negative bacilli.  Antimicrob Agents Chemother. 1996;  40 1412-1418
    PubMedGoogle Scholar
  • 34 Aaron S D, Ferris W, Henry D A, Speert D P, Macdonald N E. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia .  Am J Respir Crit Care Med. 2000;  161 1206-1212
    PubMedGoogle Scholar
  • 35 Middleton P G, Kidd T J, Williams B. Combination aerosol therapy to treat Burkholderia cepacia complex.  Eur Respir J. 2005;  26 305-308
    CrossrefPubMedGoogle Scholar
  • 36 Goss C H, Otto K, Aitken M L, Rubenfeld G D. Detecting Stenotrophomonas maltophilia does not reduce survival of patients with cystic fibrosis.  Am J Respir Crit Care Med. 2002;  166 356-361
    CrossrefPubMedGoogle Scholar
  • 37 Karpati F, Malmborg A S, Alfredsson H, Hjelte L, Strandvik B. Bacterial colonisation with Xanthomonas maltophilia: a retrospective study in a cystic fibrosis patient population.  Infection. 1994;  22 258-263
    CrossrefPubMedGoogle Scholar
  • 38 Graff G R, Burns J L. Factors affecting the incidence of Stenotrophomonas maltophilia isolation in cystic fibrosis.  Chest. 2002;  121 1754-1760
    CrossrefPubMedGoogle Scholar
  • 39 Elting L S, Khardori N, Bodey G P, Fainstein V. Nosocomial infection caused by Xanthomonas maltophilia: a case-control study of predisposing factors.  Infect Control Hosp Epidemiol. 1990;  11 134-138
    PubMedGoogle Scholar
  • 40 Carmeli Y, Samore M H. Comparison of treatment with imipenem vs. ceftazidime as a predisposing factor for nosocomial acquisition of Stenotrophomonas maltophilia: a historical cohort study.  Clin Infect Dis. 1997;  24 1131-1134
    PubMedGoogle Scholar
  • 41 Vu-Thien H, Moissenet D, Valcin M, Dulot C, Tournier G, Garbarg-Chenon A. Molecular epidemiology of Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans in a cystic fibrosis center.  Eur J Clin Microbiol Infect Dis. 1996;  15 876-879
    CrossrefPubMedGoogle Scholar
  • 42 Denton M, Todd N J, Kerr K G, Hawkey P M, Littlewood J M. Molecular epidemiology of Stenotrophomonas maltophilia isolated from clinical specimens from patients with cystic fibrosis and associated environmental samples.  J Clin Microbiol. 1998;  36 1953-1958
    PubMedGoogle Scholar
  • 43 Friedman N D, Korman T M, Fairley C K, Franklin J C, Spelman D W. Bacteraemia due to Stenotrophomonas maltophilia: an analysis of 45 episodes.  J Infect. 2002;  45 47-53
    CrossrefPubMedGoogle Scholar
  • 44 Goss C H, Mayer-Hamblett N, Aitken M L, Rubenfeld G D, Ramsey B W. Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis.  Thorax. 2004;  59 955-959
    CrossrefPubMedGoogle Scholar
  • 45 Gladman G, Connor P J, Williams R F, David T J. Controlled study of Pseudomonas cepacia and Pseudomonas maltophilia in cystic fibrosis.  Arch Dis Child. 1992;  67 192-195
    PubMedGoogle Scholar
  • 46 Demko C A, Stern R C, Doershuk C F. Stenotrophomonas maltophilia in cystic fibrosis: incidence and prevalence.  Pediatr Pulmonol. 1998;  25 304-308
    CrossrefPubMedGoogle Scholar
  • 47 Marchac V, Equi A, Le Bihan-Benjamin C, Hodson M, Bush A. Case-control study of Stenotrophomonas maltophilia acquisition in cystic fibrosis patients.  Eur Respir J. 2004;  23 98-102
    CrossrefPubMedGoogle Scholar
  • 48 Jones R N. Resistance patterns among nosocomial pathogens: trends over the past few years.  Chest. 2001;  119 397S-404S
    CrossrefPubMedGoogle Scholar
  • 49 Zhang L, Li X Z, Poole K. Fluoroquinolone susceptibilities of efflux-mediated multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Burkholderia cepacia .  J Antimicrob Chemother. 2001;  48 549-552
    CrossrefPubMedGoogle Scholar
  • 50 Babalova M, Blahova J, Lesicka-Hupkova M, Krcmery Sr V, Kubonova K. Transfer of ceftazidime and aztreonam resistance from nosocomial strains of Xanthomonas (Stenotrophomonas) maltophilia to a recipient strain of Pseudomonas aeruginosa ML-1008.  Eur J Clin Microbiol Infect Dis. 1995;  14 925-927
    CrossrefPubMedGoogle Scholar
  • 51 Blahova J, Kralikova K, Krcmery Sr V, Chmelarova E, Torsova V. Two nosocomial strains of Stenotrophomonas maltophilia transferring antibiotic resistance to Proteus mirabilis P-38 recipient strain.  J Chemother. 1998;  10 22-24
    PubMedGoogle Scholar
  • 52 Carroll K C, Cohen S, Nelson R et al.. Comparison of various in vitro susceptibility methods for testing Stenotrophomonas maltophilia .  Diagn Microbiol Infect Dis. 1998;  32 229-235
    CrossrefPubMedGoogle Scholar
  • 53 Qamruddin A O, Alkawash M A, Soothill J S. Antibiotic susceptibility of Stenotrophomonas maltophilia in the presence of lactoferrin.  Antimicrob Agents Chemother. 2005;  49 4425-4426
    CrossrefPubMedGoogle Scholar
  • 54 Alkawash M, Head M, Alshami I, Soothill J S. The effect of human lactoferrin on the MICs of doxycycline and rifampicin for Burkholderia cepacia and Pseudomonas aeruginosa strains.  J Antimicrob Chemother. 1999;  44 385-387
    CrossrefPubMedGoogle Scholar
  • 55 Clermont D, Harmant C, Bizet C. Identification of strains of Alcaligenes and Agrobacterium by a polyphasic approach.  J Clin Microbiol. 2001;  39 3104-3109
    CrossrefPubMedGoogle Scholar
  • 56 Wellinghausen N, Wirths B, Poppert S. Fluorescence in situ hybridization for rapid identification of Achromobacter xylosoxidans and Alcaligenes faecalis recovered from cystic fibrosis patients.  J Clin Microbiol. 2006;  44 3415-3417
    CrossrefPubMedGoogle Scholar
  • 57 Liu L, Coenye T, Burns J L, Whitby P W, Stull T L, LiPuma J J. Ribosomal DNA-directed PCR for identification of Achromobacter (Alcaligenes) xylosoxidans recovered from sputum samples from cystic fibrosis patients.  J Clin Microbiol. 2002;  40 1210-1213
    CrossrefPubMedGoogle Scholar
  • 58 Tan K, Conway S P, Brownlee K G, Etherington C, Peckham D G. Alcaligenes infection in cystic fibrosis.  Pediatr Pulmonol. 2002;  34 101-104
    CrossrefPubMedGoogle Scholar
  • 59 Ronne Hansen C, Pressler T, Hoiby N, Gormsen M. Chronic infection with Achromobacter xylosoxidans in cystic fibrosis patients: a retrospective case control study.  J Cyst Fibros. 2006;  5 245-251
    CrossrefPubMedGoogle Scholar
  • 60 Krzewinski J W, Nguyen C D, Foster J M, Burns J L. Use of random amplified polymorphic DNA PCR to examine epidemiology of Stenotrophomonas maltophilia and Achromobacter (Alcaligenes) xylosoxidans from patients with cystic fibrosis.  J Clin Microbiol. 2001;  39 3597-3602
    CrossrefPubMedGoogle Scholar
  • 61 Gomez-Cerezo J, Suarez I, Rios J J et al.. Achromobacter xylosoxidans bacteremia: a 10-year analysis of 54 cases.  Eur J Clin Microbiol Infect Dis. 2003;  22 360-363
    CrossrefPubMedGoogle Scholar
  • 62 Saiman L, Chen Y, Tabibi S et al.. Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis.  Clin Microbiol. 2001;  39 3942-3945
    CrossrefPubMedGoogle Scholar
  • 63 Bergogne-Berezin E, Towner K J. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features.  Clin Microbiol Rev. 1996;  9 148-165
    PubMedGoogle Scholar
  • 64 Coenye T, Goris J, Spilker T, Vandamme P, LiPuma J J. Characterization of unusual bacteria isolated from respiratory secretions of cystic fibrosis patients and description of Inquilinus limosus gen. nov., sp. nov.  J Clin Microbiol. 2002;  40 2062-2069
    CrossrefPubMedGoogle Scholar
  • 65 Forster D H, Daschner F D. Acinetobacter species as nosocomial pathogens.  Eur J Clin Microbiol Infect Dis. 1998;  17 73-77
    PubMedGoogle Scholar
  • 66 Rahal J J, Urban C. Acinetobacter .  Semin Respir Crit Care Med. 2000;  21 341-348
    Article in Thieme ConnectPubMedGoogle Scholar
  • 67 Go E S, Urban C, Burns J et al.. Clinical and molecular epidemiology of Acinetobacter infections sensitive only to polymyxin B and sulbactam.  Lancet. 1994;  344 1329-1332
    CrossrefPubMedGoogle Scholar
  • 68 Coenye T, Falsen E, Hoste B et al.. Description of Pandoraea gen. nov. with Pandoraea apista sp. nov., Pandoraea pulmonicola sp. nov., Pandoraea pnomenusa sp. nov., Pandoraea sputorum sp. nov. and Pandoraea norimbergensis comb. nov.  Int J Syst Evol Microbiol. 2000;  50 887-899
    CrossrefPubMedGoogle Scholar
  • 69 Moore J E, Reid A, Millar B C et al.. Pandoraea apista isolated from a patient with cystic fibrosis: problems associated with laboratory identification.  Br J Biomed Sci. 2002;  59 164-166
    PubMedGoogle Scholar
  • 70 Yabuuchi E, Kosako Y, Yano I, Hotta H, Nishiuchi Y. Transfer of two Burkholderia and an Alcaligenes species to Ralstonia gen. Nov.: proposal of Ralstonia pickettii (Ralston, Palleroni and Doudoroff 1973) comb. Nov., Ralstonia solanacearum (Smith 1896) comb. Nov. and Ralstonia eutropha (Davis 1969) comb. Nov.  Microbiol Immunol. 1995;  39 897-904
    CrossrefPubMedGoogle Scholar
  • 71 Labarca J A, Trick W E, Peterson C L et al.. A multistate nosocomial outbreak of Ralstonia pickettii colonization associated with an intrinsically contaminated respiratory care solution.  Clin Infect Dis. 1999;  29 1281-1286
    CrossrefPubMedGoogle Scholar
  • 72 Stelzmueller I, Biebl M, Wiesmayr S et al.. Ralstonia pickettii: innocent bystander or a potential threat?.  Clin Microbiol Infect. 2006;  12 99-101
    CrossrefPubMedGoogle Scholar
  • 73 Coenye T, Goris J, De Vos P, Vandamme P, LiPuma J J. Classification of Ralstonia pickettii-like isolates from the environment and clinical samples as Ralstonia insidiosa sp. nov.  Int J Syst Evol Microbiol. 2003;  53 1075-1080
    PubMedGoogle Scholar
  • 74 Burns J L, Van Dalfsen J M, Shawar R M et al.. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis.  J Infect Dis. 1999;  179 1190-1196
    CrossrefPubMedGoogle Scholar
  • 75 Wellinghausen N, Essig A, Sommerburg O. Inquilinus limosus in patients with cystic fibrosis, Germany.  Emerg Infect Dis. 2005;  11 457-459
    PubMedGoogle Scholar
  • 76 Schmoldt S, Latzin P, Heesemann J, Griese M, Imhof A, Hogardt M. Clonal analysis of Inquilinus limosus isolates from six cystic fibrosis patients and specific serum antibody response.  J Med Microbiol. 2006;  55 1425-1433
    PubMedGoogle Scholar
  • 77 Chiron R, Marchandin H, Counil F et al.. Clinical and microbiological features of Inquilinus sp. isolates from five patients with cystic fibrosis.  J Clin Microbiol. 2005;  43 3938-3943
    CrossrefPubMedGoogle Scholar
  • 78 Saiman L, Siegel J. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission.  Am J Infect Control. 2003;  31 S1-S62
    CrossrefPubMedGoogle Scholar
  • 79 Ramsey B W. To cohort or not to cohort: how transmissible is Pseudomonas aeruginosa?.  Am J Respir Crit Care Med. 2002;  166 906-907
    CrossrefPubMedGoogle Scholar
  • 80 Armstrong D S, Nixon G M, Carzino R et al.. Detection of a widespread clone of Pseudomonas aeruginosa in a pediatric cystic fibrosis clinic.  Am J Respir Crit Care Med. 2002;  166 983-987
    CrossrefPubMedGoogle Scholar
  • 81 Speert D P, Campbell M E, Henry D A et al.. Epidemiology of Pseudomonas aeruginosa in cystic fibrosis in British Columbia, Canada.  Am J Respir Crit Care Med. 2002;  166 988-993
    CrossrefPubMedGoogle Scholar
  • 82 Geddes D M. Of isolates and isolation: Pseudomonas aeruginosa in adults with cystic fibrosis.  Lancet. 2001;  358 522-523
    CrossrefPubMedGoogle Scholar
  • 83 Davies G, McShane D, Davies J C, Bush A. Multiresistant Pseudomonas aeruginosa in a pediatric cystic fibrosis center: natural history and implications for segregation.  Pediatr Pulmonol. 2003;  35 253-256
    CrossrefPubMedGoogle Scholar
  • 84 Duff A J. Psychological consequences of segregation resulting from chronic Burkholderia cepacia infection in adults with CF.  Thorax. 2002;  57 756-758
    CrossrefPubMedGoogle Scholar

Jane C DaviesM.B.Ch.B. 

Department of Pediatric Respiratory Medicine, Royal Brompton Hospital

Sydney St., London SW3 6NP, UK

Email: j.c.davies@ic.ac.uk

      >